combined BRAF-MEK inhibitors

Browse trials
V2  
List  

treatment    comparator  death (overall survival)  progression or death (progression free survival PFS)  objective response (ORR) recurrence free survival distant metastasis free survival aaa     
Encorafenib plus binimetinibmelanoma, in all type of patients vs vemurafenib- by 46% ----
Trametinib + dabrafenib melanoma, in all type of patients vs dabrafenib by 37% by 37% ----
Trametinib + dabrafenib melanoma, in all type of patients vs vemurafenib by 31% by 44% ----
Trametinib + dabrafenib melanoma, in all type of patients vs placebo by 43% by 53% --- by 49%
Trametinib + dabrafenib melanoma, in all type of patients vs SOC------
Trametinib + dabrafenib melanoma, in adjuvant setting vs placebo by 43% by 53% --- by 49%
Trametinib + dabrafenib melanoma, in adjuvant setting vs SOC------
Vemurafenib and cobimetinibmelanoma, in all type of patients vs vemurafenib- by 49% ----